Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HSTM vs WORX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSTM Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 10–0 Matrix Metrics)

HSTM Overall Winner 6-Pillar Tally: HSTM 4 – 1 WORX (1 Tie) Matrix Metrics: HSTM 10 – 0 WORX

As of Nov 16, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSTM carries a Unified Composite Score of 55.8/100 (HOLD) at $27.68 (30.1x Forward P/E, 7.8% operating margin), whereas WORX carries 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSTM vs WORX
HSTM NASDAQ Head-to-Head Winner
HealthStream Inc
Services-Computer Programming, Data Processing, Etc.
$27.68
-1.04% 1D
Market Cap $855.8M
TTM Revenue $328M
Forward P/E 30.1x
Beta / 30D Vol 0.39β · 48% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 28
RSI-14: 28.5 · SMA20: $31.74 · SMA50: $31.07
WORX NASDAQ
SC WORX Corp
Services-Computer Processing & Data Preparation
$1.15
-6.5% 1D
Market Cap $1.7M
TTM Revenue $2.9M
Forward P/E N/M
Beta / 30D Vol 23.01β · 208% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 15.0 Fund 31.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 71
RSI-14: 71.4 · SMA20: $0.24 · SMA50: $0.24

6-Pillar Scorecard Institutional Category Breakdown (HSTM 4 – 1 WORX)

Columns: Metric · HSTM · WORX
1. Valuation Multiples HSTM
Forward P/E 30.1x N/M
Trailing P/E 40.0x N/M
PEG Ratio 2.95x N/M
EV / Revenue 2.6x 0.6x
2. Growth & Scale HSTM
Revenue Growth (YoY) +8.9% +3.4%
Earnings Growth (YoY) -10.0% +0.0%
TTM Revenue (USD) $328M $2.9M
Market Cap $855.8M $1.7M
3. Profitability & Quality HSTM
Gross Margin 64.7% 44.7%
Operating Margin 7.8% -20.1%
Net Profit Margin 6.2% -80.5%
Return on Equity (ROE) 5.5% -38.1%
4. Balance Sheet & Cash Flow HSTM
Cash Generation (TTM) $45M EBITDA -$914,262
Cash Flow Margin 13.6% EBITDA Mgn -31.2%
Net Cash / Leverage $13.13 Book/Sh · 5.5% ROE $77.66 Book/Sh · -38.1% ROE
Dividend Yield 0.48% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 21.1% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat WORX
OpEx & R&D Intensity 56.9% of Rev ($187M) 64.8% of Rev ($1.9M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSTM (10) vs WORX (0)
Institutional Metric HSTM WORX Criterion Row Edge
Market Capitalization
Scale
$855.8M $1.7M Larger Scale HSTM
Trailing P/E Ratio
Valuation
40.0x N/M Lower Multiple HSTM
Forward P/E Ratio
Valuation
30.1x N/M Lower Multiple HSTM
Revenue Growth (YoY)
Growth
+8.9% +3.4% Higher Growth HSTM
Operating Margin (TTM)
Profitability
7.8% -20.1% Higher Margin HSTM
Net Profit Margin
Profitability
6.2% -80.5% Higher Margin HSTM
Return on Equity (ROE)
Capital Efficiency
5.5% -38.1% Higher ROE HSTM
52-Week Range Position
Momentum
51% ($20–$36) 17% ($0–$6) Stronger Trend HSTM
Beta / 30D Volatility
Risk Regime
0.39β · 48% Vol 23.01β · 208% Vol Lower Realized Risk HSTM
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite HSTM
Trailing 12M Revenue (USD)
Operating Scale
$328M $2.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.7% 44.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.95x PEG · 2.6x EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$45M EBITDA ($13.13 Book/Sh · 5.5% ROE) -$914,262 ($77.66 Book/Sh · -38.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HSTM +0.22 pp
HSTM: -16.45% · WORX: -16.67%
3M Horizon WORX +198.06 pp
HSTM: +30.32% · WORX: +228.38%
6M Horizon WORX +314.92 pp
HSTM: +12.43% · WORX: +327.35%
1Y Horizon WORX +250.12 pp
HSTM: +12.66% · WORX: +262.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HSTM vs WORX. Trailing 12-month operating profitability (HSTM 7.8% vs WORX -20.1%) and valuation multiples (HSTM 30.1x vs WORX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HSTM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$328M
Gross Margin64.7%
Op. Margin7.8%
ROE / Fwd P/E5.5% · 30.1x
WORX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.9M
Gross Margin44.7%
Op. Margin-20.1%
ROE / Fwd P/E-38.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSTM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WORX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WORX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSTM Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $855.8M market capitalization and 7.8% operating margin.
OpEx & R&D Reinvestment 56.9% of Rev ($187M)
90D Engineering Disclosures 0 Published
WORX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.7M market capitalization and -20.1% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($1.9M)
90D Engineering Disclosures 0 Published

Investor FAQ HSTM vs WORX Key Questions & Quantitative Answers

As of Nov 16, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSTM carries a Unified Composite Score of 55.8/100 (HOLD) at $27.68 (30.1x Forward P/E, 7.8% operating margin), whereas WORX carries 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin). Technically, HSTM sits in a Neutral phase (RSI 28.5, UNCLASSIFIED options structure) and WORX sits in a Markup phase (RSI 71.4, UNCLASSIFIED options structure).

HSTM leads the Growth & Scale pillar: HSTM posts +8.9% YoY revenue growth and -10.0% YoY earnings growth on $328M TTM revenue (64.7% gross margin, 7.8% operating margin), compared with WORX at +3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (44.7% gross margin, -20.1% operating margin). On trailing 12-month operating scale, HSTM generates $328M in USD-normalized revenue versus $2.9M for WORX. In operating R&D and SG&A reinvestment, HSTM deploys 56.9% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($1.9M) (0 disclosures) for WORX.

HSTM screens cheaper on headline valuation multiples. HSTM trades at 30.1x Forward P/E, 40.0x Trailing P/E, 2.95x PEG, and 2.6x EV/Revenue (13.6% EBITDA margin), whereas WORX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-31.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSTM (5.5% ROE) versus WORX (-38.1% ROE) capital efficiency.

In options market volatility and institutional positioning, HSTM carries 21.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 48% Vol realized risk). By comparison, WORX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (23.01β · 208% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.